In a retrospective review of 579 patients with metastatic NSCLC, the incidence of brain metastasis was highest in NSCLC patients with ROS1 (36%) and ALK (34%) mutations/fusions, followed by EGFR (28%) and KRAS (28%). This evidence concerns the gene EGFR and non-small cell lung carcinoma.